
Biology
Osteoporosis is filed under women's health. It appears in menopause guidance, it is screened for after fifty, and most men assume it has nothing to do with them.
Men account for roughly a third of fragility fractures. A man who breaks a hip is more likely to die in the following year than a woman who breaks one, and the figure is not close.
Testosterone is central to how a man's skeleton is built and maintained. What happens when you supplement it is a stranger story, and the largest trial produced a result nobody expected.
Bone is not inert. It is demolished and rebuilt continuously, and the balance between those two processes determines whether you gain or lose density.
Testosterone influences that balance in two ways, and the second one surprises most men.
Directly, through androgen receptors on bone cells, stimulating the cells that build.
Indirectly, through conversion to oestradiol. Aromatase converts a portion of your testosterone into oestrogen, and oestrogen restrains the cells that break bone down.
Here is the part that overturns the usual framing. In population studies of older men, low oestradiol is more consistently associated with bone loss and fracture than low testosterone is. The European guideline on male osteoporosis states it plainly: most data point to oestradiol, with no clear association between testosterone levels and bone loss.
Men spend a great deal of effort trying to lower their oestrogen. For your skeleton, that is the wrong direction. How to lower oestrogen in men makes the same point: the goal is proportion, never zero.
Peak bone mass is built in your twenties, and testosterone exposure during those years determines the size of the account you spend from later.
Severe hypogonadism is a well-established cause of osteoporosis in men. So are several situations men do not connect to bone at all.
Age-related decline is a weaker risk factor than most of these. A man of sixty whose testosterone drifted down over three decades is in a different position from a man on androgen deprivation therapy.
Three large trials examined what testosterone does to bone, and they answered increasingly demanding questions.
The Testosterone Trials bone study gave testosterone to older men with low levels for one year. Volumetric bone density and estimated bone strength both increased, more in the spine than the hip.
T4Bone, a substudy within T4DM, ran for two years with detailed imaging. Cortical volumetric density rose about 3 per cent, and density increased at the lumbar spine and hip.
A meta-analysis of 26 randomised trials covering 2,319 men found lumbar spine density up 3.7 per cent and femoral neck density up 1.8 per cent at twelve months.
Consistent, replicated, and not in dispute: testosterone increases bone density in men with low levels.
Every one of those trials measured density. None was large enough or long enough to measure the thing that actually matters.
TRAVERSE included a fracture substudy in more than 5,000 hypogonadal men, with fractures confirmed by imaging or surgery. It was designed to settle the question.
It found more fractures on testosterone, not fewer. Hazard ratio 1.43, confidence interval 1.04 to 1.97.
Steven Nissen, the trial chair, was direct about the implication: men with a history of osteoporosis probably should not be taking testosterone, and certainly should not take it to reduce fracture risk, because it appears to increase that risk.
Two large facts sitting in contradiction. Density up, fractures up.
The pattern of fractures is the clue.
Most occurred at the ankle, wrist and ribs — sites characteristic of falls and impacts, not of the vertebral and hip fractures that signal fragile bone. And the curves separated early, before any bone change could plausibly have occurred.
The leading hypothesis is behavioural rather than skeletal. Men on testosterone feel better, have more energy, and become more active. Activity increases exposure to injury, and it increases faster than tendons, ligaments and neuromuscular control adapt.
In other words, the fractures may reflect men doing more, sooner, than their connective tissue was ready for.
That is a hypothesis, and the trial was not designed to test it. TRAVERSE recorded no data on falls, physical activity or bone density, and it counted all fractures rather than the fragility fractures that define osteoporosis.
But the practical conclusion holds regardless of mechanism: higher bone density did not translate into fewer broken bones.
Testosterone is not an osteoporosis treatment. Antiresorptive drugs remain first-line for male osteoporosis, and that position is now firmer, not weaker.
If you have osteoporosis and low testosterone, you need both conversations. Treat the hypogonadism if it is symptomatic. Treat the osteoporosis with a drug that has fracture data behind it. Do not let one substitute for the other.
If you start testosterone and feel dramatically better, that is when to be careful. The energy arrives before the connective tissue adapts. Build load gradually rather than returning to what you lifted at thirty in your first fortnight. TRT before and after covers the realistic timeline.
Bone density gains are still real, and for a man with genuine hypogonadism they are a legitimate secondary benefit. They are not a reason to start.
The interventions with fracture evidence behind them are not hormonal.
Resistance training and impact. Bone responds to load. Lifting is the only lifestyle intervention that reliably builds it, and it also improves balance, which prevents the falls that cause fractures in the first place. Given the TRAVERSE pattern, that second benefit may matter as much as the first. Does lifting increase testosterone covers the hormonal side, and the free workout generator will build a plan.
Protein and calcium. Bone is roughly half protein by volume. Older men routinely undereat it.
Vitamin D, if deficient. Correcting a genuine deficiency matters. Supplementing beyond that does not. Sunlight and testosterone covers the wider picture.
Alcohol and smoking. Both are established, dose-related risk factors. The alcohol question covers where the line sits.
Not being underweight. Low body weight is a stronger predictor of male fracture than most men expect.
Men are screened far less than women, and the threshold for asking is lower than most realise. A DXA scan is quick, painless and cheap.
Worth raising if any of these apply:
One technical point worth knowing: densitometry in men over fifty is interpreted against a female reference database, on international recommendation. If your result looks confusing, that is why.
Testosterone matters for male bone, mostly through its conversion to oestradiol, and severe deficiency genuinely causes osteoporosis.
Testosterone treatment reliably increases bone density. It did not reduce fractures in the only trial large enough to measure them, and it may have increased them.
That gap between density and fractures is the most important thing on this page. It is a reminder that a number improving on a scan is not the same as an outcome improving in a life.
If your bones are the concern, the answer is a scan, a drug with fracture evidence if you need one, and a barbell. Testosterone belongs in that conversation only if you are hypogonadal and symptomatic, and even then for other reasons.
Does low testosterone cause osteoporosis in men?
Severe hypogonadism does, and is a recognised cause of secondary osteoporosis. Age-related decline is a weaker factor, and in older men low oestradiol predicts bone loss more consistently than low testosterone.
Does TRT improve bone density?
Yes. A meta-analysis of 26 trials found lumbar spine density up 3.7 per cent and femoral neck up 1.8 per cent at twelve months, with the largest gains in men with the lowest starting levels.
So does TRT prevent fractures?
No. The TRAVERSE fracture substudy found more fractures on testosterone than placebo, with a hazard ratio of 1.43. Most were at the ankle, wrist and ribs, suggesting increased injury exposure rather than weaker bone.
Should I take testosterone for osteoporosis?
No. Antiresorptive drugs remain first-line, and the trial chair advised that men with osteoporosis should be cautious about testosterone rather than using it for fracture prevention.
Why does oestrogen matter for a man's bones?
Because oestradiol restrains the cells that break bone down. Testosterone converts to it via aromatase, and in older men oestradiol is the better predictor of bone loss. Aggressively suppressing oestrogen works against your skeleton.
When should a man get a bone scan?
After any fracture from a standing-height fall past fifty, if you are on or have had androgen deprivation therapy, after three months or more of glucocorticoids, if you have lost over four centimetres of height, or with long-standing untreated hypogonadism.
Sources: Snyder PJ, Bauer DC, Ellenberg SS et al., Testosterone treatment and fractures in men with hypogonadism, N Engl J Med 2024;390(3):203-11 · Snyder PJ et al., Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial, JAMA Intern Med 2017;177(4):471-9 · Ng Tang Fui M et al., Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT, J Clin Endocrinol Metab 2021;106(8):e3143-58 · Kanis JA et al., Evidence-based guideline for the management of osteoporosis in men, Nat Rev Rheumatol 2024;20:241-51 · Kafel H, Basaria S, Testosterone and bone health in men, Curr Osteoporos Rep 2026;24:24 · Educational only, not medical advice. Osteoporosis diagnosis and treatment should be managed by a doctor.
Keep reading: TRT side effects · How to lower oestrogen in men · Does lifting increase testosterone · Testosterone recovery after steroids · Is TRT safe for your heart · Free workout generator
The Testosterone Blueprint covers the complete system — sleep, training, nutrition, supplements and bloodwork, with a step-by-step plan you can start this week.
Get the book →